1.59  -0.03 (-1.85%)		10-16 16:00
Open: 1.63 High: 1.66 Volume: 388,276		Pre. Close: 1.62 Low: 1.585 Market Cap: 171(M)

Short term
Mid term
Targets	6-month :	2.37	1-year :	2.72
Resists	First :	2.03	Second :	2.32
Pivot price	1.74
Supports	First :	1.54	Second :	1.28
MAs	MA(5) :	1.62	MA(20) :	1.8
	MA(100) :	1.9	MA(250) :	3.14
MACD	MACD :	-0.2	Signal :	-0.1
%K %D	K(14,3) :	9.1	D(3) :	6.6
RSI	RSI(14): 32.5
52-week	High :	6.3	Low :	1.54

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NGEN ] has closed above bottom band by 13.5%. Bollinger Bands are 44.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.66 - 1.67	1.67 - 1.68
Low:	1.56 - 1.57	1.57 - 1.58
Close:	1.57 - 1.59	1.59 - 1.6

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Mon, 28 Sep 2026
What Does NervGen Pharma's (NASDAQ:NGEN) Latest Move Mean for Penny Stocks Investors? - Kalkine Media

Thu, 20 Aug 2026
NervGen (NGEN) Results Check: Available Metrics Are Broadly in Line for the Current Session; Share Response: The Stock Loses 1.14% in Latest Trading - Earnings Surprise Score - www.dars.gov.et

Thu, 20 Aug 2026
NervGen (NGEN) Earnings Update: Available Metrics Are Broadly Near Expectations in the Latest Reading; Stock Move - dars.gov.et

Thu, 20 Aug 2026
NervGen (NGEN) Results Check: Available Metrics Are Broadly in Line for the Current Session; Share Response: The Stock Loses 1.14% in Latest Trading - Revenue Per Share - https://www.dars.gov.et/

Thu, 20 Aug 2026
NervGen (NGEN) Earnings Update: Available Metrics Are Broadly Near Expectations in the Latest Reading; Stock Move - www.dars.gov.et

Fri, 22 May 2026
NervGen Pharma Corp. Announces Pricing for $60 Million Underwritten Public Offering of Common Shares and Warrants | NGEN Stock News - Quiver Quantitative

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	108 (M)
Shares Float	95 (M)
Held by Insiders	15.6 (%)
Held by Institutions	11.2 (%)
Shares Short	5,830 (K)
Shares Short P.Month	5,440 (K)

EPS	-0.57
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.11
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-37.8 %
Return on Equity (ttm)	-757.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.3
Qtrly Earnings Growth	0 %
Operating Cash Flow	-26 (M)
Levered Free Cash Flow	38 (M)

PE Ratio	-2.79
PEG Ratio	0
Price to Book value	13.25
Price to Sales	0
Price to Cash Flow	-6.67

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.